The Benefit of Quantitative Imaging:
Know More. Move Faster.
With advances in technology the drug development industry is demanding analysis that is exceptionally precise and reflects a high degree of sensitivity to change. Quantitative imaging meets that need.
Quantitative imaging can reduce late-stage attrition dramatically by offering more accurate information much earlier in the drug development process. As an example, DCE-MRI is able to provide information about blood flow and vascular permeability in tumors. This information allows a relatively small trial to quickly determine whether an anti-angiogenic or vascular disruptive agent is having the desired effect. Whereas Phase I clinical trials normally focus on dosage and safety, studies that incorporate quantitative imaging can also test for drug efficacy, offering information that can save millions of dollars by allowing companies to better prioritize their drug pipelines and make more confident go/no-go decisions much earlier.
Benefits of Quantitative Imaging:
- Scientists can test a compound's method of action and lay the foundation for a more streamlined clinical trial process from Phase I through Phase III by obtaining critical information about efficacy.
- Proves or disproves mechanism of action or concept
- Provides a direct window into the effects of a drug candidate
- Detects efficacy signal and measures safety
- Reduces necessary trial sample size
- Enables sponsor to make key adjustments in mid-trial
- Algorithm driven analysis yields results faster than radiologist driven analysis
- Provides information for basis of a quicker "go/no-go" decision
- Provides the quickest path to the pharmacy shelf